Versartis Inc(NASDAQ:VSAR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Earnings per share were $-0.67. Analysts had estimated an EPS of $-0.84.
Versartis Inc (VSAR) shares turned negative on Thursdays trading session with the shares closing down -0.17 points or -1.50% at a volume of 64,634. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.5015. The peak price level was also seen at $11.5015 while the days lowest was $10.99. Finally the shares closed at $11.15. The 52-week high of the shares is $19.76 while the 52-week low is $6.17. According to the latest information available, the market cap of the company is $328 M.
Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, Joshua T Brumm (Chief Financial Officer) sold 1,448 shares at $10.63 per share price.Also, On Jun 17, 2016, Paul Westberg (Sr. VP, Business Development) sold 725 shares at $10.63 per share price.On Nov 13, 2015, R Scott Greer (director) purchased 10,000 shares at $10.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Versartis Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone VRS-317 for growth hormone deficiency (GHD) an orphan disease. The Company’s products include VRS-317 and XTEN Technology. VRS-317 combines the rhGH amino acid sequence utilized in rhGH products with a half-life extension technology XTEN to enable less frequent administration. The Company has initiated a Phase III clinical study of VRS-317 in pediatric growth hormone deficient patients. XTEN is a recombinant polypeptide that when genetically fused to a therapeutic payload of interest extends the in vivo half-life of these peptides and proteins in a tunable manner.